Thoratec Takes Steps Into PCI-Support Market With EU Roll-Out Of HeartMate PHP
This article was originally published in The Gray Sheet
Executive Summary
The company plans a targeted roll-out of its heart pump in select European markets following a CE mark for the device, indicated to help stabilize patients during high-risk percutaneous coronary interventions.
You may also be interested in...
Thoratec Set To Begin U.S. Trial Of Catheter Heart Pump To Assist PCI
FDA has conditionally approved a 425-patient trial, called SHIELD II, comparing Thoratec's HeartMate PHP to Abiomed's Impella 2.5. The company expects the study to begin in the third quarter.
Impella 2.5 PMA Gives Abiomed Big Growth Potential For High-Risk PCIs
The approval, the first for a percutaneous hemodynamic support device, frees Abiomed's hand to market the miniature blood pump to a relatively broad patient population, analysts note.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.